NCT04274023终止2 期
Phase II Study on TSR-042 in Advanced Clear Cell Sarcoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 3
- 试验地点
- 1
- 主要终点
- Overall Response Rate
研究概览
简要总结
Phase II,single arm study designed to explore the activity of TSR-042, an immunotherapy agent, in patients with a diagnosis of advanced or metastatic clear cell sarcoma (CCS).
详细描述
Phase II, single arm, not randomized, European multicentric study designed to explore the activity of TSR-042, a human monoclonal anti-PD-1 inhibitor, in a population of patients with a diagnosis of advanced/metastatic clear cell sarcoma (CCS).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Written informed consent
- •Histological centrally confirmed diagnosis of clear cell sarcoma
- •Availability of archived tumor tissue block, or 15 slides.
- •Locally advanced disease
- •Measurable disease based on RECIST 1.1
- •Patient can be naive or previously treated with 1 or 2 systemic regimens given for recurrent and/or metastatic disease
- •Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2
- •Adequate bone marrow function
- •Adequate organ function
- •Cardiac ejection fraction ≥50%
- •At least 18 years of age on day of signing informed consent.
- •Non-pregnant female patients
- •Non-ot breastfeed during the study for 90 days after the last dose of study treatment.
- •Male participant agrees to use an adequate method of contraception
- •No history of arterial and/or venous thromboembolic event within the previous 12 months.
- •Participant receiving corticosteroids may continue as long as their dose is stable for least 4 weeks prior to initiating protocol therapy.
- •Patients who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
排除标准
- •Participant must not be simultaneously enrolled in any interventional clinical trial
- •Previous treatment with any non-investigational agents within 14 days of first day of study drug dosing.
- •Must not have received investigational therapy ≤ 4 weeks, or within a time interval less than at least 5 half-lives of the investigational agent, whichever is shorter, prior initiating protocol therapy
- •Other primary malignancy with <5 years clinically assessed disease-free interval, except basal cell skin cancer, cervical carcinoma in situ, or other neoplasms judged to entail a low risk of relapse
- •Previous treatment with radiation therapy within 14 days of first day of study drug dosing, or patients who have not recovered from adverse events due to agents administered more than 4 weeks earlier
- •Has known active central nervous system (CNS) metastases, leptomeningeal metastases, and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are stable, have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment. This exception does not include carcinomatous meningitis which is excluded regardless of clinical stability
- •Has active, non-infectious pneumonitis
- •Has an active infection requiring systemic therapy
- •Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agents
- •Has received a live vaccine within 30 days of planned start of study therapy
- •Major surgery within 3 weeks prior to study entry
- •Any one of the following currently or in the previous 6 months:
- •Myocardial infarction, congenital long QT syndrome, Torsades de Pointes, arrhythmias right bundle branch block and left anterior hemiblock unstable angina coronary/peripheral artery bypass graft, symptomatic congestive heart failure New York Heart Association Class III or IV, cerebrovascular accident, or transient ischemic attack symptomatic pulmonary embolism. Ongoing cardiac dysrhythmias of Grade >=3, atrial fibrillation of any grade,or QTcF interval >470 msec
- •Severe and/or uncontrolled medical disease
- •Patient experienced ≥ Grade 3 immune-related AE with prior immunotherapy
- •Participant has a diagnosis of immunodeficiency or has receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to initiating protocol therapy
- •Any known active hepatitis B or hepatitis C
- •Any known history of human immunodeficiency virus
- •Subjects who have current active hepatic or biliary disease (with exception of patients with Gilbert's syndrome, asymptomatic gallstones, liver metastases or stable chronic liver disease per investigator assessment)
- •Expected non-compliance to medical regimens
- •Known history of interstitial lung disease
- •Active autoimmune disease that has required systemic treatment in the past 2 years
- •Known severe hypersensitivity reactions to monoclonal antibodies, any history of anaphylaxis, or uncontrolled asthma
研究组 & 干预措施
TSR-042 arm
Experimental
TSR-042 at a dose of 500 mg in IV infusion (given over t30-minutes) every 21 days for the first 4 doses, followed by 1.000 mg on day 1 of every 42 day.
干预措施: TSR-042 (Drug)
结局指标
主要结局
Overall Response Rate
时间窗: At week 12
Response rate according Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
次要结局
- Immune-related RECIST (ir-RECIST) response rate(At weeks 6, 12, 24, 36, 48, 60, 72, 84, 96)
- Progression Free Survival (PFS)(At 3 and 5 years)
- Overall Survival(At 3 and 5 years)
- Choi criteria response rate(At weeks 6, 12, 24, 36, 48, 60, 72, 84, 96)
- Clinical Benefit Rate(Month 6)
- Adverse events related to the treatment(Week 3, week 6, week 9, week 12, week 18, week 24, week 36, week 48, week 60, week 72)
- Growth Modulation Index (GMI)(At weeks 6, 12, 24, 36, 48, 60, 72, 84, 96)
- Quality of Life according the 30 questions European Organization for Research and Treatment of Cancer Quality of Life Questionnaire(Day1 Cycle 2, Day 1 Cycle 3, Every 3 cycles (Day1Cyle6, Day1Cycle 9, …) and through study completion, an average of 1 year)
- Quality of Life according the questionnaire Euro Quality Of Life 5 Domains (EQ-5D)(Day1 Cycle 2, Day 1 Cycle 3, Every 3 cycles (Day1Cyle6, Day1Cycle 9, …) and through study completion, an average of 1 year)
- Safety according the Patient Reported Outcome according Common Terminology Criteria for Adverse Events (PRO-CTCAE)(Day1 Cycle 2, Day 1 Cycle 3, Every 3 cycles (Day1Cyle6, Day1Cycle 9, …) and through study completion, an average of 1 year)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
Phase II study on clear cells sarcomaEUCTR2016-004368-21-ITITALIAN SARCOMA GROUP21
尚未招募
1 期
PSMA-specific CAR-T Cell TherapyPSMA Positive Tumors or Tumor TissuesNCT04429451Shenzhen Geno-Immune Medical Institute100
招募中
2 期
A Study of Atlacabtagene Autoleucel CAR T-cells for Adults With Relapsed Large B-cell LymphomaLarge B-cell LymphomaDiffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedPrimary Mediastinal Large B-cell Lymphoma (PMBCL)Transformed Non-Hodgkin LymphomaNCT06486051Malaghan Institute of Medical Research60
终止
1 期
TAC T-cells for the Treatment of HER2-positive Solid TumorsHER2 Positive Gastric CancerMetastatic HER2 Positive Gastroesophageal Junction CancerNCT04727151Triumvira Immunologics, Inc.28
终止
1 期
THEMBA II T-Cell Vaccine: Vaccination With saRNA COVID-19 VaccinesCOVID-19NCT05370040ImmunityBio, Inc.60